LENSAR Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw 18% revenue growth, record adjusted EBITDA, and a 20% rise in recurring revenue, with ALLY system adoption driving market share gains and profitability. Gross margin improved to 59% (52% excluding a tariff refund), and the installed base expanded globally.
-
The meeting covered board elections, auditor ratification, and executive compensation votes. All proposals passed, with directors re-elected, auditor confirmed, and annual advisory votes on compensation approved. No questions were raised by stockholders.
-
Revenue declined 5% year-over-year due to lower system sales, but recurring revenue grew 9% and now represents 94% of total revenue. The company is rebuilding momentum post-merger termination, with international placements resuming and strong recurring revenue expected to drive future growth.
Fiscal Year 2025
-
2025 saw strong recurring revenue and procedure growth despite acquisition-related disruptions, with LENSAR regaining independence and focusing on expanding its installed base and international reach. Gross margins remained healthy, and positive adjusted EBITDA was achieved.
Fiscal Year 2024
-
Record revenue and system placements in 2024 drove 27% annual growth, with recurring revenue exceeding $40 million and strong U.S. and international expansion. Positive adjusted EBITDA was achieved, and 2025 guidance calls for even higher revenue growth and continued market share gains.
-
Record Q3 revenue rose 38% year-over-year, driven by international ALLY system placements and strong recurring revenue growth. U.S. procedure market share reached 20%, with continued expansion expected as new systems ramp up.
-
ALLY's advanced imaging and AI-driven laser system is transforming cataract surgery, delivering superior clinical outcomes, significant cost savings, and increased revenues for surgical centers and surgeons. Rapid U.S. market share gains and international expansion signal strong growth potential.
-
Record Q2 with 17 ALLY placements and $12.6M revenue, up 5% year-over-year, driven by strong U.S. and global procedure growth. EU and Taiwan clearances enable international expansion, with robust backlog and positive adjusted EBITDA.